# Supplemental Digital Content 9. Seropositivity rates of antibodies against each dengue serotype at baseline (pre-dose 1) and 28 days post-dose 1 of CYD-TDV administered concomitantly or sequentially with Tdap vaccine in baseline dengue seropositive participants - FAS

|  |  |  |
| --- | --- | --- |
|  | **Concomitant****(N=338)** | **Sequential****(N=342)** |
| **Component** | **Time point** | **n/M** | **%** | **95% CI** | **n/M** | **%** | **95% CI** |
| **Serotype 1 [PRNT50 - 1/dil]** | **Pre-dose 1** | 291/314 | 92.7 | 89.2, 95.3 | 294/315 | 93.3 | 90.0, 95.8 |
| **Post-dose 1** | 306/313 | 97.8 | 95.4, 99.1 | 310/315 | 98.4 | 96.3, 99.5 |
| **Serotype 2 [PRNT50 - 1/dil]** | **Pre-dose 1** | 308/314 | 98.1 | 95.9, 99.3 | 304/315 | 96.5 | 93.8, 98.2 |
| **Post-dose 1** | 313/313 | 100.0 | 98.8, 100.0 | 312/315 | 99.0 | 97.2, 99.8 |
| **Serotype 3 [PRNT50 - 1/dil]** | **Pre-dose 1** | 300/314 | 95.5 | 92.6, 97.5 | 306/315 | 97.1 | 94.6, 98.7 |
| **Post-dose 1** | 313/313 | 100.0 | 98.8, 100.0 | 314/315 | 99.7 | 98.2, 100.0 |
| **Serotype 4 [PRNT50 - 1/dil]** | **Pre-dose 1** | 292/314 | 93.0 | 89.6, 95.6 | 307/315 | 97.5 | 95.1, 98.9 |
| **Post-dose 1** | 311/313 | 99.4 | 97.7, 99.9 | 315/315 | 100.0 | 98.8, 100.0 |

CI, confidence interval; FSA, full analysis set; M: number of participants with available data for the relevant endpoint; n, sample number; PRNT50, 50% plaque reduction neutralization test

\*Seropositivity to each dengue serotype was defined as antibody titers ≥10 (1/dil)